IL135799A0 - Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration - Google Patents

Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration

Info

Publication number
IL135799A0
IL135799A0 IL13579998A IL13579998A IL135799A0 IL 135799 A0 IL135799 A0 IL 135799A0 IL 13579998 A IL13579998 A IL 13579998A IL 13579998 A IL13579998 A IL 13579998A IL 135799 A0 IL135799 A0 IL 135799A0
Authority
IL
Israel
Prior art keywords
methods
nervous system
central nervous
neuronal regeneration
mammalian central
Prior art date
Application number
IL13579998A
Other languages
English (en)
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA 2219683 external-priority patent/CA2219683A1/en
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of IL135799A0 publication Critical patent/IL135799A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL13579998A 1997-10-28 1998-10-28 Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration IL135799A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA 2219683 CA2219683A1 (en) 1997-10-28 1997-10-28 Immunological composition and its method of use to transiently disrupt mammalian central nervous system myelin to promote neuronal regeneration
CA2251410 1998-10-16
PCT/CA1998/000997 WO1999021581A1 (en) 1997-10-28 1998-10-28 Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration

Publications (1)

Publication Number Publication Date
IL135799A0 true IL135799A0 (en) 2001-05-20

Family

ID=25679779

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13579998A IL135799A0 (en) 1997-10-28 1998-10-28 Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration
IL135799A IL135799A (en) 1997-10-28 2000-04-24 Immunological compositions to transiently alter mammalian central nervous system myelin to promote neuronal regeneration

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL135799A IL135799A (en) 1997-10-28 2000-04-24 Immunological compositions to transiently alter mammalian central nervous system myelin to promote neuronal regeneration

Country Status (11)

Country Link
US (2) US6548061B1 (de)
EP (1) EP1047449B1 (de)
JP (1) JP2001521008A (de)
AT (1) ATE249241T1 (de)
AU (1) AU748143B2 (de)
DE (1) DE69818106T2 (de)
DK (1) DK1047449T3 (de)
ES (1) ES2210829T3 (de)
IL (2) IL135799A0 (de)
PT (1) PT1047449E (de)
WO (1) WO1999021581A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002542299A (ja) * 1999-04-28 2002-12-10 ユニバーシティ・オブ・ブリティッシュ・コロンビア ミエリン特異性抗体および補体タンパク質を含むニューロン再生用組成物
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US10058471B2 (en) * 2014-02-21 2018-08-28 William M. Vaughan System and method of using hyperbaric oxygen therapy for treating concussive symptoms and musculoskeletal injuries and for pre-treatment to prevent damage from injuries
AU2015244039B2 (en) 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
MX2017012939A (es) 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
EP3523331A1 (de) 2016-10-07 2019-08-14 Novartis AG Chimäre antigenrezeptoren zur behandlung von krebs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002003A1 (en) * 1989-08-04 1991-02-21 Board Of Regents, The University Of Texas System Methods and compositions; purified preparation of neural progenitor regulatory factor
US6020140A (en) * 1991-08-09 2000-02-01 Washington University Autoantibodies and their targets in the diagnosis of peripheral neuropathies
ES2140463T3 (es) * 1992-06-12 2000-03-01 Cephalon Inc Prevencion y tratamiento de la neuropatia periferica.
US5714385A (en) * 1995-05-10 1998-02-03 Genentech, Inc. Media for culturing schwann cells
US6228598B1 (en) * 1998-10-02 2001-05-08 Washington University Antibodies to heparan sulfate glycosaminoglycans in the diagnosis of polyneuropathies

Also Published As

Publication number Publication date
AU9617998A (en) 1999-05-17
AU748143B2 (en) 2002-05-30
ES2210829T3 (es) 2004-07-01
WO1999021581A1 (en) 1999-05-06
DK1047449T3 (da) 2004-01-26
EP1047449A1 (de) 2000-11-02
EP1047449B1 (de) 2003-09-10
IL135799A (en) 2011-01-31
US6548061B1 (en) 2003-04-15
JP2001521008A (ja) 2001-11-06
DE69818106T2 (de) 2004-06-17
ATE249241T1 (de) 2003-09-15
US6969516B1 (en) 2005-11-29
PT1047449E (pt) 2004-04-30
DE69818106D1 (de) 2003-10-16

Similar Documents

Publication Publication Date Title
IL135799A0 (en) Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration
Narayanan et al. Biosynthesis and regulation of type V collagen in diploid human fibroblasts.
KR910001057A (ko) 이중특이성 및 올리고특이성 일가 및 올리고가 수용체. 이의 제조방법 및 이의 용도
DK1194167T3 (da) Immunoterapi af autoimmune sygdomme under anvendelse af B-cellespecifikke antistoffer
NL300372I1 (nl) Hybride immunoglobulinen voor gebruik bij therapeutische werkwijzen
ATE151113T1 (de) Fusionsproteine von monomeren und dimeren von antikörperfragmenten
DE69119278D1 (de) Monoklonaler Antikörper, der mit einer neuen HLA-Determinante auf MHC-Klasse-I-Moleküle reagiert, und Verfahren zur Aktivierung von Lymphozyten
MX7235E (es) Procedimiento para preparar una solucion inyectable intravenosamente de globulina de suero inmune
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
ATE248605T1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
EP0097518A3 (en) Monoclonal antibody
DK121788D0 (da) Il-6, fremgangsmaade til dets fremstilling samt dets anvendelse
ATE403001T1 (de) Antigenbindungsfragmente die spezifisch krebszellen nachweisen, nukleotide die für diese fragmente kodieren, und deren verwendung zur vorbeugung und zum nachweis von krebs
ATE112687T1 (de) Mutanten des hiv-1 hüllproteins mit fehlenden hypervariabelen domänen.
BR9810409A (pt) Métodos e composições para a modulação de responsividade a corticosteróides
AU3066489A (en) Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
DE68925593D1 (de) Antikörper-Heterokonjugate zur Regulation der Lymphozytenaktivität
DE69531290D1 (de) Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen
PT99770A (pt) Processo para a preparacao de receptores de glutamato acoplados com proteina g de mamiferos
AU4626389A (en) Use of minoxidil for wound healing
EA199900409A1 (ru) Растворимые рецепторы бета-лимфотоксина, антитела против рецепторов лимфотоксина и антитела против лимфотоксиновых лигандов как терапевтические агенты для лечения иммунологических заболеваний
CA2253078A1 (en) Immunological composition and its method of use to transiently disrupt mammalian central nervous system myelin to promote neuronal regeneration
EA199900522A1 (ru) Полипептиды, кодируемые геном, подобным гену липазы человека, композиции и методы
DE69432472D1 (de) Verfahren zur hemmung der phagozytose
NO892125D0 (no) Kombinasjon av angiotensin-omvandlende-enzymhemmere med kaliumkanal-modulatorer samt deres anvendelse i legemidler.

Legal Events

Date Code Title Description
FF Patent granted